Back to Stakeholders
Dormant / Unclear
Categories
1 domain / 1 area
Entheon BiomedicalCSE: ENBI
1 Trial
Canadian psychedelic biotech that sold its DMT Phase 1 clinical trial assets to Cybin in 2022. Following the sale, Entheon has operated as a near-shell company with minimal employees and no active drug development programme.
Quick Facts
- Type
- Public Biotech
- Ticker
- CSE: ENBI
- Website
- Visit